Popular immunotherapy target turns out to have a surprising buddy

The majority of current cancer immunotherapies focus on PD-L1. This well-studied protein turns out to be controlled by a partner, CMTM6, a previously unexplored molecule that is now suddenly also a potential therapeutic target.